EIMC Pharmaceuticals

Pharmacy Market

PRNewswire | July 18, 2023

Karyopharm Therapeutics Inc. a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to the development program of selinexor for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis. "Fast Track Designation for selinexor highlights its...

Business Insights

NextRNA Therapeutics | March 02, 2022

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Prnewswire | September 30, 2020

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed conten...

Business Insights

Telix Pharmaceuticals Limited | April 11, 2022

Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma. Olaratumab was originally developed by Lilly as a monoclonal antibody targeting Pl...